All In Biotech

Drug Trial Radar · NCT06258148

A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial of TG103 Injection Monotherapy Subjects With Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

465

Actual

Start

Apr 15, 2024

Primary completion

Jan 23, 2026

Study completion Jan 23, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-parallel, multicenter phase 3 clinical trial to evaluate the efficacy of TG103 injection 7.5mg and 15mg once a week monotherapy compared with placebo in subjects with type 2 diabetes with poor glycemic control after diet and exercise.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • TG103Drug

    TG103 injection, 7.5mg, 15 mg, SC, once a week

  • PlaceboDrug

    Placebo, SC, once a week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in glycosylated hemoglobin (HbA1c)Time frame: Baseline through Week28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.